Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-3774
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience ; day:16 ; month:8 ; year:2022 ; pages:1-7
International journal of hematology ; (16.8.2022), 1-7
- Urheber
-
Spałek, Adrianna
Wieczorkiewicz-Kabut, Agata
Koclęga, Anna
Woźniczka, Krzysztof
Węglarz, Patryk
Boral, Kinga
Kata, Dariusz
Zielińska, Patrycja
Helbig, Grzegorz
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12185-022-03434-5
- URN
-
urn:nbn:de:101:1-2022110318325470448594
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:31 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Spałek, Adrianna
- Wieczorkiewicz-Kabut, Agata
- Koclęga, Anna
- Woźniczka, Krzysztof
- Węglarz, Patryk
- Boral, Kinga
- Kata, Dariusz
- Zielińska, Patrycja
- Helbig, Grzegorz
- SpringerLink (Online service)
Ähnliche Objekte (12)
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Murine Models of Steroid Refractory Graft-versus-Host Disease
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Impact of cytopenias and early versus late treatment with ruxolitinib in patients with steroid-refractory acute or chronic graft-versus-host disease
A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Fecal microbiota transfer for refractory intestinal graft-versus-host disease — experience from two German tertiary centers
Ruxolitinib for the treatment of patients with steroid-refractory GVHD : : an introduction to the REACH trials
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD